Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $3.59B
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: -84.07%
• EPS Growth: -157.71%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 101,474,945
• 10 Day Avg. Volume: 2,016,690
• 30 Day Avg. Volume: 1,679,709
• PEG Ratio: -0.03
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 32.14
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: 28.11
• Enterprise Value/Gross Profit: -4.40
• Enterprise Value/Ebitda: -3.64
• 1Y Price Target: $42.45
• Price Target Upside: 32.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -4.65
• Revenue Forecast (FY): $42.90M

• Rating: 53 Neutral
• Price Target: $34.00 ▲(6.08% Upside)

The score is held back primarily by weak financial performance (declining revenue, very large losses, and negative cash flows). Technicals are constructive with strong trend and positive MACD, but overbought RSI adds near-term risk. Corporate events are a meaningful positive (extended runway and regulatory/clinical progress), while valuation support is limited due to losses and a negative P/E.

Positive Factors

Extended Cash Runway

A reported cash position of roughly $1.25B and a runway into 2029 materially reduces near-term financing risk, allowing management to fund pivotal trials, regulatory activities, and commercialization planning. This durable liquidity supports execution across multiple programs without immediate capital raises.

Regulatory Progress for BEAM-302

FDA alignment on an accelerated pathway and inclusion in CMC pilots is a structural positive: it shortens the clinical-to-market timeline and raises the probability of an earlier approval contingent on biomarker endpoints. This reduces development risk and can materially improve program economics long term.

Proprietary Base Editing Platform

Beam's proprietary base editing platform and multi-indication pipeline create a durable competitive advantage, enabling multiple internal programs and partnering/licensing opportunities. Platform-driven R&D can generate scalable, repeatable value across genetic diseases and support long-term revenue diversification.

Negative Factors

Declining Revenue

Trailing revenue declines point to difficulty converting R&D progress into commercial or partnership revenue; persistent top-line weakness undermines scalability and raises dependence on financing. Over a 2-6 month horizon, continued revenue erosion could constrain reinvestment in programs.

Severe Negative Profitability

Very large negative margins and deep operating losses indicate high burn and that profitability is distant absent major commercial success. This structural loss profile increases fundraising frequency risk, dilutes shareholders over time, and pressures management to prioritize capital allocation carefully.

Weak Cash Flow Trends

Significant negative operating and free cash flow and a steep -90.3% FCF decline reflect an unsustainable internal cash generation profile. While one-time proceeds bolstered liquidity, persistent negative cash flow necessitates external funding or asset monetization, increasing execution and financing risk.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Beam Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potential future product sales. The company partners with pharmaceutical companies and research institutions to co-develop its therapies, often receiving upfront payments, milestone payments as projects advance, and royalties on future sales. Additionally, Beam may monetize its proprietary technologies through licensing deals, allowing other companies to use their base editing technology in exchange for fees. As their product candidates advance through clinical trials and toward commercialization, potential sales of successful therapies will also contribute to revenue.

Beam Therapeutics Financial Statement Overview

Summary

Beam Therapeutics faces significant financial challenges, with declining revenues, substantial losses, and negative cash flows. The company has a manageable debt level, but profitability and cash flow issues persist. While there are some signs of potential revenue growth, the overall financial health is weak, requiring strategic improvements to achieve stability and profitability.

Income Statement

Beam Therapeutics has experienced declining revenue and negative profit margins over the TTM period. The company shows a negative revenue growth rate of -7.58% and a significant net profit margin of -901.34%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges. Despite these issues, the company has shown some historical revenue growth, suggesting potential for future improvement.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.16, indicating a relatively low level of leverage. However, the return on equity is negative at -42.86%, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a reasonable level of stockholders' equity relative to its total assets, suggesting some financial stability despite profitability challenges.

Cash Flow

Beam Therapeutics has negative operating and free cash flows, with a free cash flow growth rate of -90.3% over the TTM period. The operating cash flow to net income ratio is -1.85, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.04, suggesting some ability to cover net losses with free cash flow, albeit limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.70M	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	-356.09M	-304.04M	377.71M	-250.67M	-180.29M	-103.16M
EBITDA	-430.13M	-393.64M	-146.95M	-324.33M	-230.06M	-128.03M
Net Income	-414.64M	-376.74M	-132.53M	-289.09M	-370.64M	-194.59M
Balance Sheet
Total Assets	1.31B	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	1.07B	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	151.42M	161.43M	172.69M	179.00M	147.64M	107.64M
Total Liabilities	345.08M	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	966.00M	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-352.36M	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-338.18M	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	-103.56M	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	479.61M	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Positive. The current price of 32.05 is above the 20-day moving average (MA) of 28.80, above the 50-day MA of 26.05, and above the 200-day MA of 21.44, indicating a bullish trend. The MACD of 1.83 indicates Negative momentum. The RSI at 60.82 is Neutral, neither overbought nor oversold. The STOCH value of 75.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.27B	-74.36	-28.17%	―	129.21%	80.35%
IMVT	56 Neutral	$5.51B	―	-95.93%	―	―	-27.70%
BEAM	53 Neutral	$3.59B	-7.23	-47.19%	―	-84.07%	-157.71%
IRON	52 Neutral	$2.91B	-13.26	-34.78%	―	―	-34.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMCR	47 Neutral	$1.67B	-56.06	-7.52%	―	27.51%	38.72%
DNLI	46 Neutral	$2.85B	-6.45	-44.44%	―	―	-5.30%

Beam Therapeutics Corporate Events

Beam Therapeutics outlines 2026 strategy and extends runway

On January 11, 2026, Beam Therapeutics outlined strategic priorities for 2026 across its genetic disease and hematology franchises, emphasizing progress in late-stage clinical programs and a substantially extended cash runway. The company reported clinical proof of concept for BEAM-302 in alpha-1 antitrypsin deficiency, treating more than 25 patients in an ongoing Phase 1/2 trial and securing U.S. FDA alignment on a potential accelerated approval pathway based on 12‑month biomarker endpoints, alongside inclusion of the program in the FDA’s CMC Development and Readiness Pilot. Beam is also advancing BEAM-301 for glycogen storage disease type Ia with a Phase 1/2 trial underway and initial data expected in 2026, and plans to disclose an additional liver-targeted program in the first half of 2026. In its hematology franchise, the company highlighted encouraging Phase 1/2 BEACON data for its sickle cell therapy risto-cel, which has fully enrolled adult and adolescent cohorts, completed manufacturing of all doses by December 2025, gained entry into the FDA’s CDRP program, and is being positioned for a biologics license application as early as year‑end 2026. Beam is simultaneously investing in next-generation in vivo gene-editing approaches for sickle cell disease, including targeted lipid nanoparticles for hematopoietic stem cell delivery and its ESCAPE platform, with a Phase 1 trial of the conditioning antibody BEAM‑103 expected to complete dosing in the first half of 2026. Financially, Beam estimated it ended 2025 with about $1.25 billion in cash, cash equivalents and marketable securities, supported in part by proceeds from Bristol-Myers Squibb’s acquisition of Orbital Therapeutics, and now projects its operating runway to extend into 2029, backing the anticipated commercial transition for risto-cel and pivotal development of BEAM‑302 and reinforcing its position as a well-capitalized emerging leader in genetic medicines.

The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics Gains $255M from Orbital Acquisition

On December 8, 2025, Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics, in which Beam Therapeutics held a 17% stake. Beam’s shares were converted into $255.1 million in cash, with potential for additional consideration, impacting its financial outlook ahead of the 2026 J.P. Morgan Healthcare Conference.

The most recent analyst rating on (BEAM) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.